Roivant Sciences Ltd. ROIV
Institutional shares held
488 Million
565K
calls
1.68M
puts
Total value of holdings
$5.27B
$6.11M
calls
$18.2M
puts
Market Cap
$7.61B
704,382,976
Shares Out.
Institutional ownership
69.28%
# of Institutions
270
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Sb Investment Advisers (Uk) LTD London, X073MShares$789 Million7.6% of portfolio
-
Viking Global Investors LP69.4MShares$749 Million2.78% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$721 Million65.04% of portfolio
-
Black Rock Inc. New York, NY36.2MShares$391 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.6MShares$385 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY20MShares$216 Million7.19% of portfolio
-
State Street Corp Boston, MA17.2MShares$185 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.2MShares$132 Million54.89% of portfolio
-
Woodline Partners LP San Francisco, CA11.2MShares$121 Million1.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$87.5 Million0.0% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 23
2024
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,702
+6.56%
|
-
|
|
Jul 23
2024
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,555
+1.93%
|
-
|
|
Jul 23
2024
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-0.26%
|
$2,365
$11.01 P/Share
|
|
Jul 23
2024
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
2,440
+2.86%
|
-
|
|
Jul 20
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-0.45%
|
$10,538
$11.0 P/Share
|
|
Jul 20
2024
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.97%
|
$120,395
$11.0 P/Share
|
|
Jul 20
2024
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-2.39%
|
$120,395
$11.0 P/Share
|
|
Jun 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,340
-0.8%
|
$23,400
$10.57 P/Share
|
|
Jun 20
2024
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.96%
|
$109,450
$10.8 P/Share
|
|
Jun 20
2024
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-2.34%
|
$109,450
$10.8 P/Share
|
|
Jun 20
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,087
-1.43%
|
$30,870
$10.8 P/Share
|
|
Jun 20
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.73%
|
$21,290
$10.8 P/Share
|
|
May 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-0.79%
|
$23,410
$10.83 P/Share
|
|
May 20
2024
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.95%
|
$120,395
$11.37 P/Share
|
|
May 20
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,363
-0.63%
|
$14,993
$11.37 P/Share
|
|
May 20
2024
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,003
-3.31%
|
$176,033
$11.37 P/Share
|
|
Apr 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,340
-0.79%
|
$25,740
$11.03 P/Share
|
|
Apr 24
2024
|
Epperly Melissa B, |
SELL
Payment of exercise price or tax liability
|
Direct |
123
-0.54%
|
$1,230
$10.9 P/Share
|
|
Apr 24
2024
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,146
+4.81%
|
-
|
|
Apr 24
2024
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
54
-0.07%
|
$540
$10.9 P/Share
|
Last 12 Months Summary
Buy / Acquisition
4.61M
Shares
From
12
Insiders
| Grant, award, or other acquisition | 161K shares |
|---|---|
| Exercise of conversion of derivative security | 4.45M shares |
Sell / Disposition
166M
Shares
From
28
Insiders
| Payment of exercise price or tax liability | 987K shares |
|---|---|
| Other acquisition or disposition | 122M shares |
| Grant, award, or other acquisition | 38.7K shares |
| Open market or private sale | 42.3M shares |